Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-23 p19-targeting dexabody
- Development stage
- Preclinical
- Lead developer
- Dextera Biosciences
- Modality
- Peptides
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
IL-23 p19-targeting dexabody is a synthetic D-protein therapeutic candidate being developed by Dextera Biosciences for the treatment of inflammatory bowel disease (IBD) and psoriasis. The drug is engineered using Dextera's proprietary "dexabody" platform, which utilizes mirror-image D-amino acids to create proteins that are resistant to proteolytic degradation by enzymes in the blood and digestive tract. This stability potentially allows for both injectable and oral delivery. The dexabody specifically binds to the p19 subunit of interleukin-23 (IL-23), thereby neutralizing the cytokine and preventing it from activating the Th17 inflammatory pathway, which is a central driver of chronic autoimmune and inflammatory conditions.
- Other names
- IL-23 p19-targeting dexabodyIL23 p19-targeting dexabodyIL 23 p19-targeting dexabody
02
Targets
IL23A (Interleukin-23 p19 Subunit)
Beyond the preview
Go deeper on IL-23 p19-targeting dexabody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-23 p19-targeting dexabody.